Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics
- PMID: 28480928
- DOI: 10.1039/c7mb00110j
Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics
Abstract
Despite the advances in tuberculosis treatment, TB is still one the most deadly infectious diseases and remains a major global health quandary. Mycobacterium tuberculosis (Mtb) is the only known mycobacterium with a high content of 3→3 crosslinks in the biosynthesis of peptidoglycan, which is negligible in most bacterial species. An Mtb lacking LdtMt2 leads to alteration of the colony morphology and loss of virulence which makes this enzyme an attractive target. Regardless of the vital role of LdtMt2 for cell wall survival, the impact of ligand binding on the dynamics of the β-hairpin flap is still unknown. Understanding the structural and dynamical behaviour of the flap regions provides clear insight into the design of the effective inhibitors against LdtMt2. Carbapenems, an specific class of β-lactam family, have been shown to inactivate this enzyme. Herein a comprehensive investigation of the flap dynamics of LdtMt2 complex with substrate and three carbapenems namely, ertapenem, imipenem and meropenem is discussed and analyzed for the first account using 140 ns molecular dynamics simulations. The structural features (RMSD, RMSF and Rg) derived by MD trajectories were analyzed. Distance analysis, particularly tip-tip SER135-ASN167 index, identified conformational changes in terms of flap opening and closure within binding process. Principal component analysis (PCA) was employed to qualitatively understand the divergent effects of different inhibitors on the dominant motion of each residue. To probe different internal dynamics induced by ligand binding, dynamic cross-correlation marix (DCCM) analysis was used. The binding free energies of the selected complexes were assessed using MM-GBSA method and per residue free energy decomposition analysis were performed to characterize the contribution of the key residues to the total binding free energies.
Similar articles
-
Targeting the cell wall of Mycobacterium tuberculosis: a molecular modeling investigation of the interaction of imipenem and meropenem with L,D-transpeptidase 2.J Biomol Struct Dyn. 2016;34(2):304-17. doi: 10.1080/07391102.2015.1029000. Epub 2015 Jul 24. J Biomol Struct Dyn. 2016. PMID: 25762064
-
Molecular insight on the non-covalent interactions between carbapenems and L,D-transpeptidase 2 from Mycobacterium tuberculosis: ONIOM study.J Comput Aided Mol Des. 2018 Jun;32(6):687-701. doi: 10.1007/s10822-018-0121-2. Epub 2018 May 29. J Comput Aided Mol Des. 2018. PMID: 29845435
-
In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.Antimicrob Agents Chemother. 2013 Dec;57(12):5940-5. doi: 10.1128/AAC.01663-13. Epub 2013 Sep 16. Antimicrob Agents Chemother. 2013. PMID: 24041897 Free PMC article.
-
Carbapenems in the USA: focus on doripenem.Expert Rev Anti Infect Ther. 2007 Oct;5(5):793-809. doi: 10.1586/14787210.5.5.793. Expert Rev Anti Infect Ther. 2007. PMID: 17914914 Review.
-
Parenteral carbapenems.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:175-80. doi: 10.1111/j.1469-0691.2007.01868.x. Clin Microbiol Infect. 2008. PMID: 18154543 Review.
Cited by
-
Targeting ebola virus VP40 protein through novel inhibitors: exploring the structural and dynamic perspectives on molecular landscapes.J Mol Model. 2021 Jan 25;27(2):49. doi: 10.1007/s00894-021-04682-8. J Mol Model. 2021. PMID: 33495861
-
Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation.J Food Biochem. 2022 May;46(5):e14085. doi: 10.1111/jfbc.14085. Epub 2022 Feb 6. J Food Biochem. 2022. PMID: 35128681 Free PMC article.
-
Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00866-17. doi: 10.1128/AAC.00866-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28760902 Free PMC article.
-
ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.Sci Rep. 2021 Jan 8;11(1):234. doi: 10.1038/s41598-020-79918-3. Sci Rep. 2021. PMID: 33420186 Free PMC article.
-
Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CLpro through high-throughput virtual screening and molecular dynamics simulation.Aging (Albany NY). 2021 Mar 7;13(5):6258-6272. doi: 10.18632/aging.202703. Epub 2021 Mar 7. Aging (Albany NY). 2021. PMID: 33678621 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
